PANTOPRAZOLE FOR THE TREATMENT OF ACID-RELATED DISEASES


Cite item

Full Text

Abstract

Pantoprazole, proton pump inhibitor (PPI), blocks basal and stimulated secretion of hydrochloric acid in the stomach by inhibiting the H+/K+-ATPase. According to the literature data and own research results, antisecretory effect of pantoprazole is comparable with that of other PPIs. The main distinguishing features of pantoprazole are the lack of interaction with simultaneously taken drugs, the drug does not accumulate in the body, dose adjustment for elderly patients with the presence of renal and hepatic failure is not required, and its effect does not depend on the genetically determined metabolic rate in the liver. Modern medical regimens with pantoprazole for the treatment of gastroesophageal reflux disease, Helicobacter pylori infection, NSAID-associated gastropathy, and for the prevention and treatment of stress ulcers and gastroduodenal bleeding are presented.

References

  1. Modlin I, Sachs G. Acid related diseases. Biology and treatment. Schnetztor-Verlag Gmbh, Konstanz., 1998. 142 р.
  2. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17(1):22-37.
  3. Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002;123:1588-97.
  4. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acidrelated disorders. Drugs 1996;5 (3):460-82.
  5. Mussig S, Witzel L, Luhmann R, et al. Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH. Eur J Gastroenterol Hepatol 1997;9(6):599-602.
  6. Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999;11(11):1277-82.
  7. Geus WP, Mathot RA, Mulder PG, et al. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori- negative subjects. Aliment Pharmacol Ther 2000;14(8):1057-64.
  8. Florent C, Forestier S. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg. Eur J Gastroenterol Hepatol 1997;9(2):195-200.
  9. Simon B, Mueller P, Gatz G, et al. Equivalent effect of pantoprazole 40 mg o.d. and esomeprazole 40 mg o.d. on intra-esophageal pH in patients with symptomatic GERD abstract. Am J Gastroenterol 2001;96(Suppl.):35.
  10. Hartmann M, Ehrlich A, Fuder H, et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 1998;12(10):1027-32.
  11. Reill L, Erhardt F, Fischer R, et al. Effect of oral pantoprazole on 24-hour intragastric pH, serum gastrin profile and drug metabolising enzyme activity in man - a placebo-controlled comparison with ranitidine (abstract no.F252). Gut 1993;34(Suppl. 4):63.
  12. Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34(5):185-94.
  13. Juurlink DN, Gomes T, Ко DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8.
  14. Fontes-Carvalho R, Albuquerque А, Araujo С, et all. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol 2011;23:396-404.
  15. Andersson T, Cederberg C, Heggelund A. The pharmacokinetics of single and repeated once daily dose of 10, 20 and 40 mg omeprazole as enteric coated granules. Drug Invest 1991;3:45-52.
  16. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997;62(6):619-28.
  17. Dominguez-Martin A, Dominguez-Munoz A, Munoz S, et al. Efficacy of six days triple therapy with pantoprazole plus clarithromycin and amoxycillin versus omeprazole plus clarithromycin and amoxycillin for H.pylori eradication (abstract no. G0438). Gastroenterology 1998;15(114 Suppl. 2):107.
  18. Broutet N, Marais A, Lamouliatte H, et al. cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol 2001;39(4):1319-22.
  19. Eissele R, Gatz G, Hole U. Equivalent efficacy of pantoprazole 40 mg and esomeprazole 40 mg in patients with GERD. Can J Gastroenterol 2002;16(Suppl. A):95.
  20. Vicari F, Belin J, Marek L. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux oesophagitis: results of a French multicentric double-blind comparative trial. Gastroenterology 1998;15(114 Suppl. 2):324.
  21. Koerner T, Schuetze R, Van Leendert R, et al. Comparable efficacy of pantoprazole 40mg vs. omeprazole MUPS 40mg in patients with GERD II/III. Gut 2002;51 (Suppl. III):166.
  22. Dupas J-L, Houcke P, Samoyeau R. Pantoprazole versus lansoprazole in French patients with reflux esophagitis. French Collaborative Pantoprazole Study Group. Gastroenterol Clin Biol 2001;25(3):245-50.
  23. Plein K, Hotz J, Wurzer H, et al. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000;12(4):425-32.
  24. Olteanu D, Balan C, Andronescu A, et al. Efficacy of pantoprazole as compared to omeprazole and misoprostol in NSAID associated gastric ulcer [abstract]. Gut 2000;47(Suppl. III):82.
  25. Bianchi Porro G, Lazzaroni M, Imbesi V, et al. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallelgroup study. Dig Liver Dis 2000;32(3):201-8.
  26. Силуянов С.В., Смирнова Г.О., Лучинкин И.Г. Кровотечения из острых язв желудка и двенадцатиперстной кишки в клинической практике // РМЖ 2009. Т. 17, № 5. С. 347-53.
  27. Schonekas H, Ahrens H, Pannewick U, et al. Comparison of two doses of intravenous pantoprazole in peptic ulcer bleeding [abstract no. P0121]. Gastroenterology 1999;116(Suppl. V Pt 2):A104202.
  28. Altana Pharma AG. Summary of product characteristics (SPC) pantoprazole 20 mg tablet [online]. Available from URL: www.altanapharma.com [Accessed 2002 Nov 8].
  29. Rimbara Е, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
  30. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997;54:581-96.
  31. Яковенко Э.П., Яковенко А.В., Илларионова Ю.В. и др. Ингибиторы протонной помпы в профилактике терапии стрессовых язв // Лечащий врач. 2010. № 2. С. 52-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies